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Abstract
Background It was hypothesised that colorectal cancer (CRC) could be diagnosed in biopsies by
measuring the combined expression of a small set of well known genes. Genes were chosen based on
their role in either the breakdown of the extracellular matrix or with changes in cellular metabolism both
of which are associated with CRC progression Findings Gene expression data derived from quantitative
real-time PCR for the solute transporter carriers (SLCs) and the invasion-mediating matrix
metalloproteinases (MMPs) were examined using a Linear Descriminant Analysis (LDA). The combination
of MMP-7 and SLC5A8 was found to be the most predictive of CRC. Conclusion A combinatorial analysis
technique is an effective method for both furthering our understanding on the molecular basis of some
aspects of CRC, as well as for leveraging well defined cancer-related gene sets to identify cancer. In this
instance, the combination of MMP-7 and SLC5A8 were optimal for identifying CRC.

Keywords
colorectal, transcripts, metalloproteinases, transporters, solute, cancer, expression, measuring,
combinatorial

Disciplines
Medicine and Health Sciences

Publication Details
Kerr, C. A., Dunne, R., Hines, B., Zucker, M., Cosgrove, L., Ruszkiewicz, A., Lockett, T. and Head, R. (2009).
Measuring the combinatorial expression of solute transporters and metalloproteinases transcripts in
colorectal cancer.. BMC Research Notes, 2 1-7.

Authors
Caroline A. Kerr, Robert Dunne, Barney Hines, Michelle Zucker, Leah Cosgrove, Andrew Ruszkiewicz,
Trevor Lockett, and Richard Head

This journal article is available at Research Online: https://ro.uow.edu.au/medpapers/572

BMC Research Notes

BioMed Central

Open Access

Short Report

Measuring the combinatorial expression of solute transporters and
metalloproteinases transcripts in colorectal cancer
Caroline A Kerr*1,2, Robert Dunne1,3, Barney M Hines1,4, Michelle Zucker1,5,
Leah Cosgrove1,5, Andrew Ruszkiewicz6, Trevor Lockett1 and Richard Head1
Address: 1CSIRO Preventative Health Flagship, CSIRO Division of Molecular and Health Technologies, CSIRO, Division of Molecular and Health
Technologies, Adelaide, SA, 5000, Australia , 2CSIRO, Division of Molecular and Health Technologies, North Ryde, NSW, 1670, Australia , 3CSIRO,
Mathematical and Information Sciences, North Ryde, NSW, 1670, Australia, 4CSIRO Division of Livestock Industries, Queensland Biosciences
Precinct, St Lucia, Qld, 4067, Australia , 5CSIRO, Division of Molecular and Health Technologies, Adelaide, SA, 5000, Australia and 6Department
of Pathology, The University of Adelaide, Adelaide, SA, 5005, Australia
Email: Caroline A Kerr* - Caroline.Kerr@csiro.au; Robert Dunne - Rob.Dunne@csiro.au; Barney M Hines - Barney.Hines@csiro.au;
Michelle Zucker - Michelle.Zucker@csiro.au; Leah Cosgrove - leah.cosgrove@csiro.au;
Andrew Ruszkiewicz - andrew.ruszkiewicz@imvs.sa.gov.au; Trevor Lockett - Trevor.Lockett@csiro.au; Richard Head - Richard.head@csiro.au
* Corresponding author

Published: 19 August 2009
BMC Research Notes 2009, 2:164

doi:10.1186/1756-0500-2-164

Received: 13 May 2009
Accepted: 19 August 2009

This article is available from: http://www.biomedcentral.com/1756-0500/2/164
© 2009 Kerr et al; licensee BioMed Central Ltd.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0),
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract
Background: It was hypothesised that colorectal cancer (CRC) could be diagnosed in biopsies by
measuring the combined expression of a small set of well known genes. Genes were chosen based
on their role in either the breakdown of the extracellular matrix or with changes in cellular
metabolism both of which are associated with CRC progression
Findings: Gene expression data derived from quantitative real-time PCR for the solute
transporter carriers (SLCs) and the invasion-mediating matrix metalloproteinases (MMPs) were
examined using a Linear Descriminant Analysis (LDA). The combination of MMP-7 and SLC5A8 was
found to be the most predictive of CRC.
Conclusion: A combinatorial analysis technique is an effective method for both furthering our
understanding on the molecular basis of some aspects of CRC, as well as for leveraging well defined
cancer-related gene sets to identify cancer. In this instance, the combination of MMP-7 and SLC5A8
were optimal for identifying CRC.

Findings
Colorectal cancer is the third-most common cancer in
males and second-most common in females worldwide
[1]. Its prevalence highlights a need to more deeply understand the molecular interactions that lead to its progression. Two important and well documented pathways in
the progression of colorectal cancer are changes in energy
source for cellular metabolism and break down of the
extracellular matrix.

Healthy colonocytes use short-chain monocarboxylates,
in particular butyrate, as their main source of energy [2].
The solute-linked carrier (SLC) SLC5A8, a Na+-coupled
transporter, and monocarboxylate transporter (MCT1)
SLC16A, are possibly vehicles by which short-chain
monocarboxylates are transported into the colonic epithelium [3-5]. SLC5A8 and SLC16A1 have been purported to
provide a mechanism for the suppression of tumour
growth in colorectal and gastric cancers [3,6] and are
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down-regulated with tumour progression [4]. As colonocytes become cancerous there is a shift in energy source
away from butyrate to glucose, resulting in increased levels of glucose in colorectal cancer cells [7] and in carcinomas [8]. Associated with this is an up-regulation of the
glucose transporter SLC2A1, which has been shown in a
significant proportion of aggressive human tumours [e.g.
[9]]. Together, these changes are believed to facilitate
tumour growth and proliferation [10].

Methods
Sample collection
Human colon tissue was sourced from the Division of Tissue Pathology, Institute of Medical and Veterinary Science, University of Adelaide. There were two sets of
normal and CRC tissues as outlined in Table 1 (for further
details of these samples [see Additional file 1 Tables S1
and S2].
Total RNA extraction, cDNA synthesis and real-time PCR
The human tissue samples were obtained from resections
of specimens and placed in OCT (optimal cutting temperature cryopreservation medium) [17], snap-frozen in liquid nitrogen and then stored at -86°C. After histological
verification RNA was extracted by placing samples in 1 ml
of Trizol® Reagent (Invitrogen, Sydney, Australia), then
homogenised using beads (mix of 2.5 mm glass and 0.1 –
1.0 mm diameter silicon-zirconium beads) in a MiniBeadbeater-8™ (BioSpec Products Inc., Oklahoma, USA) and
extracted according to Invitrogen's instructions. Samples
were then further processed using RNAeasy mini spin columns (QIAGEN, Doncaster, Australia) with contaminating DNA being removed via DNase on-column digestion
as per the manufacturer's instructions. Similarly, cultured
cells that were at least 70% confluent were extracted
directly using the RNAeasy spin columns. The integrity of
RNA samples from Study 2 and the cell lines were checked
using a Bioanalyzer 2100 (Agilent Technologies) [18]. All
of the RNA samples were then quantified using a NanoDrop® ND-1000 Spectrophotometer. Samples were then
diluted to100 ng/ul.

Matrix metalloproteinases (MMPs) are a family of zincand calcium-dependent proteolytic enzymes that degrade
macromolecules of the extracellular matrix. Members of
this family, such as MMP-2, -9 and -7, have been shown
to be associated with the breakdown of type IV collagen
and the basement membrane. They have been implicated
in tumour progression and invasion in human cancer tissues [11-13]. The proteolytic activity of some MMPs (e.g.
MMP-2, -9 and -14) can be suppressed by Reversioninducing cysteine-rich protein with kazal motifs (RECK)
[14]. Decreased expression of RECK is believed to result in
increased invasion, metastasis and angiogenesis [reviewed
by [15]] and is associated with poor prognosis in cancer
patients [16].
This paper investigates genes in combination from two
previous well defined processes in colorectal cancer. The
abundance of transcripts from well described candidate
genes implicated in either the tumorigenic process or metabolic changes associated with carcinogenesis were examined in human colorectal cancer cell lines and human
cancer and healthy colonic tissues. In particular, the
expression of the nutrient transporter genes (SLC2A1,
SLC16A1 and SLC5A8), genes encoding proteins involved
in tissue remodelling and tumour invasion (MMP-2, -7, 9 and -12, and the MMP regulator RECK), were examined
in two sets of normal human colon and colorectal tumour
samples and in four human colorectal cancer cell lines.
The study used a combinatorial transcript expression bioinformatic approach to leverage described information on
a small gene set in order to discriminate between normal
and colorectal tumour tissue and help to define interrelationships between processes known to change during carcinogenesis.

cDNA was synthesised using SuperScript II (Invitrogen)
reverse transcriptase (Invitrogen) using 1 ug of RNA per
20 uL reaction and incubated as outlined in the manufacturer's instructions. Real-time PCR assays were conducted
using off-the shelf optimised and guaranteed TaqMan®
Gene Expression Assays (Applied Biosystems, Foster City,
California, USA), that consisted of primers and a probe
for the specific genes (Table 2). Three housekeeping genes
were used: the conventional reference gene 18S ribosomal
RNA (18S) [e.g. [19]], as well as a ribosomal protein (large
P0, a component of the 60S subunit) and HUWE1 (see
Table 2). The latter two were identified as suitable using a

Table 1: Summary of tissue sample details^

Site

Normal
Dukes A

Study 1
Study 2

Left
Right
Left
Right
Transverse

4
1
6
6
2

2
2
1
1
-

Tumour pathology
Dukes B
Dukes C
1
4
4
-

2
2
2
1

Dukes D
1
-

^see Additional file 1 for more details.
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Table 2: Gene and assay details.

Gene Name and Symbol

Genbank accession numbers TaqMan Primer/Probe ID Product size
(bp)

Eukaryotic 18S rRNA.
HECT, UBA and WWE domain containing 1 (HUWE1).

X_03205.1
NM_031407
NM_005703
NM_017627
XM_497119
NM_053275.3
NM_0011002.3
NM_002426
NM_004530

Hs99999901_s1
Hs00328354_m1

187
74

Hs99999902_m1

105

Hs00159178_m1
Hs00234422_m1

62
83

NM_002423
NM_004994

Hs00159163_m1
Hs00234579_m1

101
54

NM_021111

Hs00221638_m1

76

NM_006516

Hs00197884_m1

70

NM_145913
NM_003051

Hs00377618_m1
Hs00161826_m1

88
110

Ribosomal protein, large, P0 (60s).
Matrix metalloproteinase 12 (MMP12).
Matrix metalloproteinase 2 (MMP2) (gelatinase A, 72 kDa
gelatinase, 72 kDa type IV collagenase).
Matrix metalloproteinase 7 (MMP7).
Metalloproteinase 9 (MMP9)(gelatinase B, 92 kDa gelatinase, 92
kDa type IV collagenase).
Reversion-inducing-cysteine-rich protein with kazal motifs
(RECK).
Solute carrier family 2 (facilitated glucose transporter) member
1: SLC2A1, alias Glut1.
Solute carrier family 5 (iodide transporter), member 8.
Solute carrier family 16, member 1 (monocarboxylic acid
transporter 1).

commercial database from Gene Logic (Gaithersburg,
Maryland, U.S.A.). The database contains information on
44928 probe-sets (HUG-133A and B Affymetrix arrays)
derived from 462 individuals covering the classes: normal
222; adenoma 29; cancer 161; and other disease 50. The
dataset was normalized using the GCRMA algorithm [20]
and then probe-sets were selected that had minimal variance across all arrays and had appreciable expression levels. The aim was to use three housekeeping genes of
varying abundance (18s as the highest and HUWEI as the
lowest) to cover the range of target transcript differential
expression. Also, the target and housekeeping gene assays
were selected where possible to prime over an intron-exon
boundary to avoid amplifying any contaminating
genomic DNA (which could otherwise bias results). The
assays were then set up in four aliquots per cDNA sample
using TaqMan® Universal PCR Master Mix commensurate
with the manufacture's instructions, except that 5 μl reaction volumes were used. Assays consisted of 20× mix of
unlabeled PCR primers and TaqMan® MGB probe (FAM
dye-labelled). Assays were run in 384-well plates on an
Applied Biosystems PRISM® 7900HT real-time thermocycler and analysed using Sequence Detection System software (version 2.3) as outlined in the TaqMan® Gene
Expression Assays protocol.
Data acquisition
Data on the expression levels of target and reference genes
were obtained in the form of crossing points [21] or
threshold (Ct) values. The target genes were then analysed
following the delta-delta Ct value procedure [22,23] with
the assumption that efficiency was 100% and amplicons

doubled each cycle. Briefly, the Ct for each housekeeping
gene (HK) was subtracted from each corresponding target
gene such that,

ΔCt normalised target gene = Ct target gene − Ct HK gene ,
The mean of the normal tissues was used to create a reference tissue value. So,
ΔCt reference = 1 / n

∑

all normal tissues

[Ct target (gene normal tissue) − Ct HK gene,]

and then,

ΔΔCt = ΔCt normalised target gene − ΔCt reference .
This process allowed for the data to be analysed for artefacts, real-time PCR repeatability and stability of HK
expression. As three HK genes were used, the process was
then repeated with each housekeeping gene and the
median calculated; the ratio of the gene expression is 2ΔΔCt.
The normalised ΔΔCt data sets were then combined and
all subset variable selection with Linear Discriminant
Analysis (LDA) was performed to ascertain the best combination of transcripts that separated tumour from normal. The error rate for the model was estimated using
'leave-one-out estimates' for cross validation [24].
Transcript expression from cultured colorectal cancer cell
lines (HT29, HCT116, Caco2 and LIM1215) was then
used to further test the optimal combinations using LDA.
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The effect of tissue sampling site (i.e. left, transverse or
right colon), the type of 'normal' and Dukes stage was also
analysed.

Results
The normalised data sets for all seven target genes for
study 1, which consisted of randomly grouped tumour
and normal, were analysed using LDA [see Additional file
1 for figure S1, Additional file 2 for the raw Ct values],
resulting in a separation of the normal and tumour samples (the leave-one-out error estimate from the LDA is
0.25, [see Additional file 1 – Figure S2]. Using an all subsets variable selection procedure with LDA created a
reduced model using only RECK and MMP-7 (see Figure
1), giving an improved leave-one-out error estimate of
0.06. Note, all the 'normal' samples clustered together
regardless of their source (i.e. from a CRC or healthy
patient). Therefore, there was no effect by the source of
'normal'.
For study 2, which consisted of paired data, the normalised data sets for all seven target genes were then analysed
using LDA [see Additional file 1 – Figure S3 and Additional file 3 for raw Ct values], resulting in separation of
the normal and tumour samples (the leave-one-out error
estimate from the LDA is 0.178, [see Additional file 1 figure S4]. This separation was further increased using an all
subsets variable selection procedure with LDA. The resultant reduced model, this time using only MMP7 and

http://www.biomedcentral.com/1756-0500/2/164

SLC5A8, had a leave-one-out error estimate from the LDA
of 0.035 (see Figure 2).
When data from both the human tissue studies were combined and LDA applied to the four classes (Study 1 normal, Study 1 tumour, Study 2 normal, Study 2 tumour);
the two sets of 'normals' could not be separated and the
two sets of 'tumours' could not be separated. This indicates that it is feasible to combine the studies. The optimal
transcript combination that separated tumour from normal was SLC5A8 and MMP-7 (see Figure 3) resulting in a
leave-one-out error estimate of 0.128. There was no effect
of sampling site (i.e., left, right or transverse colon) or
Duke's stage on the expression of MMP-7 or SLC5A8.
Then, as an exercise to test the mathematics of this
approach, the two studies plus CRC cell line data [see
Additional file 1 for Figure S5 and Additional file 3 for raw
Ct values] were then combined. The maximum separation
between tissue types (normals, as opposed to tumour tissue plus cell lines) occurred with the transcript combination of MMP-7, RECK and SLC5A8 (see Figure 4).

Discussion
This communication investigated expression patterns of
transcripts associated with processes involved in the
development of colorectal cancer. Genes examined were
the solute transporters SLC2A1, SLC5A8 and SLC16A1,
which are associated with changes in the cellular import

normal
Figure
Box
mal
(healthy)
plot1of the
and
optimal
tumour
transcript
colon tissue
model
from
forStudy
separating
1
norBox plot of the optimal transcript model for separating normal (healthy) and tumour colon tissue from
Study 1. LDA scores resulted from the combined normalised gene data set reduced down to an optimal model of
RECK and MMP-7.

tumour

Figure
Box
mal
(healthy)
plot2of the
and
optimal
tumour
transcript
colon tissue
model
from
forStudy
separating
2
norBox plot of the optimal transcript model for separating normal (healthy) and tumour colon tissue from
Study 2. LDA scores resulted from the combined normalised gene data reduced down to an optimal model of MMP7
and SLC5A8.
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nor2
Box plot of the optimal transcript model for separating normal (healthy) and tumour colon tissue from
Studies 1 and 2. LDA scores resulted from the combined
normalised gene data set reduced down to an optimal model
of MMP7 and SLC5A8.

of energy sources, and MMP-2, MMP-7, MMP-9 and
MMP-12, which are related to the breakdown of the extracellular matrix, and the MMP negative regulator, RECK.
Individual differential gene expression patterns were
established for normal and cancerous tissue samples.
When the data were combined, a combination of MMP-7
and SLC5A8 (and, to a lesser extent, RECK) provided the
greatest separation between healthy colon tissue and
colorectal cancer (tissue or cell lines). One possible interpretation of these results is that the mechanisms which act
to break down the extracellular matrix and promote
tumour invasion also induce MMP negative regulation.
Whilst in parallel, SLC5A8 levels in tumours were reduced
compared to normal tissue and cell lines, which is consistent with previous studies [4] showing an association
between SLC5A8 down-regulation and tumour progression.
This study has demonstrated that it is advantageous to use
a combinatorial approach to defining biomarkers of carcinogenesis processes compared to using individual candidate transcript markers. Others have used systematic
approaches when analysing transcripts for cancer biomarkers (e.g. pancreatic cancer by [25]) and have shown that
markers, which individually are suboptimal, can be combined to yield higher sensitivity and specificity. Even
though our study uses a small patient tissue library, it
demonstrates a proof-of-concept for the combinatorial

http://www.biomedcentral.com/1756-0500/2/164

Figure
The
ear
gene
Discriminant
first
data
4two
setsLinear
Analysis
Discriminants
(LDA) of (LD1
the combined
and LD2)normalised
from LinThe first two Linear Discriminants (LD1 and LD2)
from Linear Discriminant Analysis (LDA) of the combined normalised gene data sets. Reduced down to an
optimal model with the transcript combination of MMP7,
SLC5A8 and RECK which separated the normal (healthy) and
the tumour colon tissue from Studies 1 and 2 and the cultured cell lines of ('empty circle' Study 1 normal, 'empty
square' Study 2 normal, 'black circle' Study 1 tumour, 'black
square' Study 2 tumour, 'black square with cross' cell lines).

approach to transcript biomarkers that now needs to be
validated in larger controlled data sets [26,27]. In addition, our technique may prove useful to validate other
colorectal cancer candidate transcripts, such as those
defined in a recent study [28] which applied a meta-analysis or genome wide studies (e.g. microarrays) to comprehensively evaluate microarray data for biomarkers.
Although using tumour-related gene expression may not
be an optimal platform for colorectal cancer detection,
this combinatorial approach demonstrates a method for
biomarker discovery based on a priori hypotheses originating from other studies that may prove useful either in
elucidating early biomarkers or in establishing auxiliary
markers of prognosis. This approach could be applied in
the clinical setting to increase the sensitivity and specificity of biomarkers by combining the analyses with other
markers [29].
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